Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma CEO Christoph Westphal, M.D., Ph.D., Joins BIO Emerging Companies Governing Board

BOSTON--(BUSINESS WIRE)--Feb. 11, 2015-- (Click to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that Flex Pharma Co-founder and CEO, Christoph Westphal, M.D., Ph.D., has been appointed to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. Dr. Westphal was Co-Founder, CEO and lead investor of Acceleron, Alnylam, Flex, Momenta, Sirtris and Verastem.

"Dr. Westphal and I have worked together closely for nearly 15 years on several important companies, including Alnylam,” commented John Maraganore, Ph.D., Alnylam CEO, BIO Board member, BIO Executive Committee member, and Chair of the BIO Emerging Company Section. “Throughout the years, I have always admired his focus on breakthrough science that has the potential to generate important new therapies to treat patients with unmet medical need. As an industry leader with a proven track record, it is a pleasure to welcome Dr. Westphal to the BIO Board, where I expect him to make strong contributions in our efforts to preserve our industry’s innovation environment for biomedical research and discovery.”

“I have collaborated with Dr. Westphal for over a decade on a number of important biotech companies,” noted Henri Termeer, former Chairman and CEO of Genzyme Corporation. “Successful entrepreneurs like Dr. Westphal continually revitalize the biotechnology industry by bringing together great scientific minds, talent and the fiscal resources required to develop breakthrough scientific discoveries into important new therapies for patients.”

"Dr. Westphal is a recognized leader in the development and growth of successful biotechnology companies,” said Ron Cohen, M.D., Acorda CEO and BIO Executive Committee member. “As co-founder, CEO and lead investor of six companies that were taken public on NASDAQ, his deep industry expertise and insights will be highly valuable contributions to BIO.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
VP, Investor Relations & Corporate Communications
irdept@flex-pharma.com